Smoking: Smoking Prevalence

Smoking prevalence describes how common smoking is within a defined population and time period. Studies often find higher rates among people with schizophrenia than in the general population, but estimates differ across countries, services and historical periods. A hospital sample may not represent everyone living with the diagnosis.

Smoking is common among people receiving care for schizophrenia, but patterns and reasons vary. Tobacco smoke and nicotine have different pharmacological roles, which matters when discussing medication interactions. Assessment should address dependence, physical health and treatment exposure without assuming that smoking is necessary for cognitive function or that cessation support is unsuitable for people with psychosis.

Explanations involve interacting social, economic, environmental and biological factors. Higher prevalence should not be interpreted as evidence that smoking is inevitable or that cessation will worsen everyone’s mental health. It also does not describe an individual’s level of dependence or readiness to change. Accurate reporting specifies the group and date rather than presenting one timeless percentage. Clinically, prevalence highlights the need for accessible support and physical healthcare. It should not normalise avoidable harm or cause services to overlook smoking simply because it is common in the population they treat.

Prevalence changes with policy, social conditions and access to cessation support. A figure from one service or decade should therefore be dated and contextualised. Higher rates highlight a need for accessible prevention and treatment, rather than justify a lower expectation of health. Services can support change while recognising individual preferences and avoiding stereotypes about everyone who has the same diagnosis.

Further reading: NICE clinical guideline; NHS Specialist Pharmacy Service.